This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Schering-Plough Misses the Mark

Schering-Plough (SGP) slid 12% after reporting an earnings miss Monday.

The drugmaker said it earned $713 million, or 45 cents a share on a GAAP basis, compared with $287 million, or 19 cents a share, in the third quarter of 2007. (The GAAP number includes a gain for acquisition-related items, including a gain on a currency option and a charge of $20 million for an upfront licensing payment.)

Excluding acquisition-related items and an upfront R&D payment, the company said it earned 28 cents a share for the quarter. Analysts surveyed by Thomson Financial were expecting 30 cents a share on revenue of $2.87 million.

Global net sales increased 9% on a GAAP basis and 12% on an adjusted basis to $2.8 billion and $3.5 billion, respectively.

Worldwide cholesterol joint-venture net sales totaled $1.3 billion, a 26% increase from $1 billion in the year-ago quarter. Schering-Plough recorded $506 million in equity income from its cholesterol joint venture with Merck (MRK - Get Report) in the 2007 third quarter vs. $390 million in the third quarter of 2006.

Global sales of Remicade, a treatment for inflammatory diseases, increased 34% to $426 million in the third quarter of 2007.

Sales of inhaled allergy treatment Nasonex increased 10% to $242 million due to increased sales in international markets. Sales of antihistamine Clarinex were flat, and sales of Claritin increased 12% to $83 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $49.03 0.37%
AAPL $93.99 0.31%
FB $102.01 0.10%
GOOG $682.40 -0.10%
TSLA $151.04 0.38%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs